» Solide Tumore und Neoplasien » Verschiedene solide Tumore/Neoplasien
Alle Linien
ARROS-1 (NVL-520-01) Phase-1/2-Studie zu NVL-520 bei Patienten mit fortgeschrittenem NSCLC und anderen soliden Tumoren (Aktiv)
BO41932 - TAPISTRY Tumordiagnostische Präzisionsimmunoonkologie und somatisches Targeting rational rational for you (TAPISTRY) Phase II - Plattformversuch (Aktiv)
BrigaPed A Phase I/II study of Brigatinib in pediatric and young adult patients with ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or other solid tumors (Aktiv)
CMCS110Z2102 A Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies (Aktiv)
CONKO-011 Rivaroxaban in the Treatment of Venous Thromboembolism (VTE) in Cancer Patients (Aktiv)
CodeBreak 101 A Phase 1b/2, Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Sotorasib Monotherapy and in Combination With Other Anti-cancer Therapies in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (Aktiv)
IMbrella B An Open Label, Multicenter Extension Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella B) (Aktiv)
LIBERAL Liberal transfusion strategy to prevent mortality and anaemia-associated, ischaemic events in elderly non-cardiac surgical patients (Aktiv)
MAESTRO Magnetic Resonance-guided Adaptive Stereotactic Body Radiotherapy for Hepatic Metastases (Aktiv)
MK-3475-587 Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) (Aktiv)
MR Linac Feasibility of Online MR-guided Radiotherapy on a 1.5T MR-Linac (Aktiv)
NEPO_MUC Neoadjuvante Strahlentherapie (N-RT) zur Behandlung von intrazerebalen Metastasen solider Tumore (Aktiv)
NOA-26 - IT-PD1 Intrathekale Anwendung von PD1-Antikörpern bei metastasierten soliden Tumoren mit leptomeningealer Erkrankung (Aktiv)
ROSETTA RandOmized Study Exploring the Combination of radioTherapy With Two Types of Acupuncture Treatment: The ROSETTA Trial (ROSETTA) (Aktiv)
SIP (CHAI) Simultane integrierte Protektion zur Schonung der kritischen Organe in der Nähe von Läsionen bei der Körperstereotaxie (Aktiv)
SPIN-MET, SPIME2013 Efficacy of Dose Intensified Radiotherapy of Spinal Metastases by Hypofractionated Radiation and IGRT hfSRT Mediated Boost (SPIN-MET) (Aktiv)
SenPET Study to Assess Safety and PET Imaging Characteristics of a Novel Senescence-specific Radiotracer [18F]FPyGal (2-[Fluorine-18]Fluoro-3-pyridinyl-β-D-galactopyranoside) (Aktiv)
Erstlinie
Abbvie M23-385 A Phase 1 first-in-human study evaluating safety, pharmacokinetics and efficacy of ABBV-706 as monotherapy and in combination with budigalimab (ABBV-181), carboplatin, or cisplatin in adult subjects with advanced solid tumors. (Aktiv)
Keynote-158, MK3475-158 Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (Aktiv)
LCNEC-ALPINE A Phase II, single-arm trial of addition of Atezolizumab to standard chemotherapy of Platinum and Etoposide for the treatment of advanced large-cell neuroendocrine cancer of the lung (Aktiv)
TAS-120-206 A Phase 2 Study of Futibatinib in Combination with PD-1 Antibody-based Standard of Care Therapy in Patients with Solid Tumors (TAS-120-206) (Aktiv)
Zweitlinie oder später
AMG305_20220073 Phase 1 First-In-Human Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors (Aktiv)
ANV600-001 EXPAND-1 A first-in-human, open-label, multicenter Phase I/II study to evaluate the safety and anti-tumor activity of ANV600 as single agent and in combination with pembrolizumab in participants with relapsed/refractory advanced solid tumors (Aktiv)
Amgen 20210023 Eine Phase-1/1b/2-Studie zur Bewertung der Sicherheit, Verträglichkeit, Pharmakokinetik, Pharmakodynamik und Wirksamkeit von AMG 193 allein und in Kombination mit Docetaxel bei Patienten mit fortgeschrittenen soliden MTAP-null-Tumoren (Aktiv)
BMS CA052-002 A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination With Nivolumab in Participants With Advanced Solid Tumors (Aktiv)
BNT211-01 A Trial to Evaluate the Safety and Efficacy of CLDN6 CAR-T +/- CLDN6 RNA-LPX (Aktiv)
BoB Module 1 A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets) (Aktiv)
CA030-001 An Investigational Immunotherapy Study of BMS-986249 Alone and in Combination With Nivolumab in Solid Cancers That Are Advanced or Have Spread (Aktiv)
CHORDOM (HIT-1 / CH.P.12C) Trial of Proton Versus Carbon Ion Radiation Therapy in Patients With Chordoma of the Skull Base (HIT-1) (Aktiv)
CHRO761A12101 Eine offene, multizentrische Phase-I/Ib-Dosisfindungs- und Expansionsstudie von HRO761 als Einzelwirkstoff und in Kombinationen bei Patienten mit fortgeschrittenen soliden Tumoren mit hoher Mikrosatelliteninstabilität oder Mismatch-Reparaturmangel Studie von HRO761 allein oder in Kombination bei Krebspatienten mit spezifischen DNA-Veränderungen, die als Mikrosatelliten-Instabilität oder Mismatch-Reparatur-Mangel bezeichnet werden (Aktiv)
CLDK378A2407 study of ceritinib in patients with advanced solid tumors and hematological malignancies characterized by genetic abnormalities of ALK (Aktiv)
CatalYm CTL-002-001 First-in-Human Study of the GDF-15 Neutralizing Antibody CTL-002 in Patients With Advanced Cancer (GDFATHER) (Aktiv)
DLL3 A Study to Test Different Doses of BI 764532 in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for Delta-Like Ligand 3 (DLL3). (Aktiv)
EDO-S101-1001 Phase-I-Studie zur Untersuchung der Sicherheit, der pharmakokinetischen Profile sowie der Wirksamkeit von Tinostamustine, einem First-in-Class alkylierenden HDACi-Fusionsmolekül, bei rezidivierenden/refraktären hämatologischen Malignomen Eine Phase-1/2-Studie zur Untersuchung der Sicherheit, Pharmakokinetik und Wirksamkeit von EDO-S101, einem erstklassigen HDACi-Fusionsmolekül (Alkylating Histone Deacetylase Inhibition) bei Patienten mit fortgeschrittenen soliden Tumoren Untersuchung der Sicherheit, Phar (Aktiv)
F8394-201 A Phase 2 Master Protocol to assess the efficacy and safety of FORE8394, an inhibitor of BRAF class 1 and class 2 alterations, in participants with cancer harboring BRAF alterations (Aktiv)
ICT01-102 (EVICTION-2) A two-part, open-label, clinical study to assess the safety, tolerability and activity of intravenous doses of ICT01 in combination with low-dose subcutaneous interleukin-2 in patients with advanced solid tumors. (EVICTION-2) (Aktiv)
IGNYTE (RPL-001-16) Eine offene, multizentrische Phase-1/2-Studie mit RP1 als Einzelwirkstoff und in Kombination mit PD1-Blockade bei Patienten mit soliden Tumoren (Aktiv)
IMA 401-101 A Phase Ia/Ib First-In-Human Clinical Trial to Evaluate the Safety, Tolerability and Initial Anti-tumor Activity of IMA401, a Bispecific T Cell Engaging Receptor Molecule (TCER®), in Patients With Recurrent and/or Refractory Solid Tumors. (Aktiv)
IMA402 (bispecific T cell engaging receptor molecule) A Phase I/II First-In-Human Clinical Trial to Evaluate the Safety, Tolerability and Anti-Tumor Activity of IMA402, a Bispecific TCER® Targeting PRAME, in Patients With Recurrent and/or Refractory Solid Tumors (Aktiv)
INFORM2-NivEnt (NCT-2017-0516) INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies (Aktiv)
INSIGHT Phase I study to evaluate the feasibility and safety of IMP321 in solid tumors (Aktiv)
KontRASt-01 Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation (Aktiv)
KontRASt-03 A Phase Ib/II, multicenter, open-label dose escalation and expansion platform study of JDQ443 with select combinations in patients with advanced solid tumor harboring the KRAS G12C mutation (Aktiv)
MCLA-128-CL01/MERUS A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (Aktiv)
MK-3475 Study of Pembrolizumab (MK-3475) in Children (Aktiv)
Olaparib / AstraZeneca A Phase I, Open-label, Parallel Group Study to Investigate Olaparib Safety and Tolerability, Efficacy and Pharmacokinetics in Paediatric Patients with Solid Tumours (Aktiv)
Proto-R-Kinder Protonentherapie bei Kindern: Prospektive Erfassung von Effizienz und Nebenwirkungen bei klinischen Standarddosen (Aktiv)
REFIT-MSS (TRIO042) Eine offene Phase-II-Multikohorten-2-Stufen-Studie zur Bewertung der Wirksamkeit und Sicherheit von Regorafenib in Kombination mit Tislelizumab bei Patienten mit ausgewählten Mismatch-Reparatur profizienten/mikrosatellitenstabilen vorbehandelten soliden Krebsarten (Aktiv)
RadCav Neoadjuvant vs. Intraoperative vs. Adjuvant Resection Cavity Radiotherapy of Brain Metastases - A Prospective Randomized Explorative Phase II Trial (Aktiv)
SATURNUS Hypofractionated stereotactic radiotherapy versus single fraction stereotactic radiotherapy to the resection cavity of brain metastases after surgical resection. (Aktiv)
SGNPDL1V-001 A Phase 1 Study of SGN-PDL1V in Advanced Solid Tumors (Aktiv)
SORATRAM Multizentrische Basket-Studie zur kombinierten CRAF- und MEK-Inhibition bei fortgeschrittenen Tumorerkrankungen mit BRAF-Mutationen und eingeschränkter Kinase-Aktivität (Aktiv)
STARVATION Short-term Starvation vs. Normal Diet before Chemotherapy of Solid Tumors (Aktiv)
STELLAR-002/XL092 A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination With Immuno-Oncology Agents in Subjects With Unresectable Advanced or Metastatic Solid Tumors (Aktiv)
TAPISTRY Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial (Aktiv)